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Abstract
Background: Point of care (POC) assays for cardiac tro-
ponins I or T (cTnI or cTnT) may accelerate the diagnosis of 
patients with suspected acute coronary syndrome (ACS). 
However, their clinical utility according to the 0  h/3  h 
algorithm recommended by the European Society of Car-
diology (ESC) for non-ST elevation myocardial infarction 
(NSTEMI) is unknown.
Methods: Blood samples from 90 patients with suspected 
ACS were obtained at hospital admission and 3  h later. 
Concentrations of cTn were determined using five POC 
assays (AQT90 FLEX cTnI and cTnT; PATHFAST™ cTnI; 
Stratus CS 200 cTnI; and Triage MeterPro cTnI) and two 
guideline-acceptable high-sensitivity (hs) immunoassays.
Results: For the diagnosis of NSTEMI (n = 15), AUCs for 
Abbott hs-cTnI and Roche hs-cTnT were 0.86 [95%  confi-
dence interval (CI), 0.75–0.96] and 0.88 (95% CI, 0.80–0.95), 
respectively, at admission, and 0.96 and 0.94, respectively, 
3  h later. With the 99th percentile cutoff, their sensitivi-
ties were 62% and 92%, respectively, at admission, and 
77% and 100%, respectively, 3  h later. The PATHFAST™ 
cTnI assay showed AUCs of 0.90 (95% CI, 0.82–0.97) and 
0.94 (95% CI, 0.89–1.00), respectively, and sensitivities of 
67% and 75% at admission and 3 h later, respectively. The 
other cTn POC assays had AUCs of 0.71 (95% CI, 0.53–0.89) 
to 0.84 (95% CI, 0.71–0.96) and 0.86 (95% CI, 0.72–0.99) to 
0.87 (95% CI, 0.75–0.99) and sensitivities of 39%–50% and 
62%–77% at admission and 3 h later, respectively.
Conclusions: PATHFAST™ cTnI assay proved itself as 
comparable to ESC-guideline acceptable hs-cTn assays. 
The lower sensitivity of the other POC assays limits their 
clinical utility and would require longer follow-up moni-
toring of patients for the safe NSTEMI rule-out.
Keywords: acute myocardial infarction; point of care 
(POC) troponin.
Introduction
The measurement of cardiac troponins I or T (cTnI or cTnT) 
complements the clinical assessment and resting 12-lead 
ECG in the diagnosis, risk stratification and therapy of 
patients with acute coronary syndrome (ACS). Patients 
showing ST elevation on electrocardiography (ECG) are 
directly referred to the catheterization laboratory without 
awaiting results of cardiac troponin tests [1]. In ACS 
patients without ST elevation (NSTE-ACS), cTn measure-
ment is indispensable to distinguish high-risk patients 
with non-ST elevation myocardial infarction (NSTEMI), 
who require rapid invasive intervention, from low-risk 
patients with unstable angina pectoris [2]. For NSTE-ACS 
patients, time to the clinical decision is strongly influ-
enced by the sensitivity of the cardiac troponin test.
Guideline-acceptable high-sensitivity (hs) assays 
measure cTn levels representing the 99th percentile 
of healthy individuals with an imprecision of 10% or 
less. According to guidelines of the European Society of 
Cardiology (ESC), cTn levels below the 99th percentile 
measured by hs-cTn assays in blood samples obtained at 
admission and 3 h later allow the safe rule out of NSTEMI. 
Conventional assays with an imprecision ranging between 
10% and 20% are considered as clinically useful but need 
follow-up time of 6 h to rule out NSTEMI [2, 3].
Due to their short turnaround time, point-of-care (POC) 
assays have the potential to accelerate the management of 
NSTE-ACS patients in the emergency department. However, 
POC cTn assays have not yet been evaluated as thoroughly 
as automated hs-cTn assays performed in central labora-
tories, which form the basis of current guidelines. As yet, 
most of them have been assigned to the scorecard catego-
ries (guideline acceptable, clinically useful or not accept-
able) based on the manufacturers’ self-declarations on 
imprecision and 99th percentiles rather than on the basis of 
publicly available reports of clinical studies [4]. Therefore, 
in a series of whole blood samples freshly obtained from 
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90 patients with suspected ACS, we compared the analyti-
cal and diagnostic performance of five point of care (POC) 
assays and two guideline-compatible central laboratory 
assays for cTnI or TnT according to the 0 h/3 h algorithm 
recommended by ESC for the NSTEMI management.
Materials and methods
Study population
The study was performed at the University Hospital Zurich (USZ) 
between January and December 2016 upon approval of the Cantonal 
Ethic Committee Zurich (KEK-ZH-Nr. 2016-00378). Patients who pre-
sented themselves on working days between 8:00 am and 6:00 pm 
with clinical symptoms suggestive for cardiac ischemia were recruited 
at the emergency department and, after providing the informed con-
sent, enrolled into the study. All diagnostic procedures including 
ECG recordings and clinical assessment were performed according to 
the standardized procedures in patients presenting with chest pain 
at the emergency department. Venous blood samples anticoagulated 
either with Li-heparinate or K-EDTA for the study purposes were col-
lected together with diagnostic specimens at hospital admission and 
again 3 h later. For some patients, blood samples were only available 
from the time point of admission. The detailed characteristics of the 
patients are provided in Table 1. All final diagnoses were adjudicated 
by an experienced cardiologist, and all ACS cases were confirmed 
through coronary angiography.
Selection of POCTs for cTn
We approached and asked six manufacturers or sale representatives 
of seven POC assays for cTnI or cTnT. Finally, Alere with Triage Meter-
Pro with Next Generation TnI, Radiometer with AQT90 FLEX for both 
cTnI and cTnT, Axonlab with PATHFAST™ Immunoanalyzer from LSI 
Medience Corporation and Siemens with Stratus CS 200 agreed to 
join the study and provided POC devices, tests and control materials 
free of charge.
cTn assays
Fresh K-EDTA whole blood samples were analyzed on the Triage 
MeterPro with Next Generation TnI (Alere, Waltham, MA, USA) for 
cTnI, whereas fresh Li-heparinate whole blood samples were ana-
lyzed on PATHFAST™ Immunoanalyzer (LSI Medience Corporation, 
Tokyo, Japan) for cTnI and on AQT90 FLEX (Radiometer, Copenhagen, 
Denmark) for both cTnI and cTnT. The blood collection tube could be 
place directly in Stratus C2 200 (Siemens, Erlangen, Germany) with 
on board centrifugation (2.5 mL of whole blood required). However, 
due to the limited sample volume available for the study, whole blood 
samples were processed in the external centrifuge, and one plasma 
aliquot (400 μL) was analyzed for the cTnI on Stratus CS 200. Remain-
ing plasma aliquots were stored frozen at −80 °C for further analysis 
for hs-cTnI on Architect i2000SR (Abbott Diagnostics Lake Bluff, IL, 
USA). The hs-TnT assay was performed on Cobas 8000 e602 modular 
analyzer (Roche Diagnostics, Rotkreuz, Switzerland) using diagnostic 
samples. Table 2 provides detailed characteristics of the cTn assays as 
stated by their manufacturers. All reagents, tests and control materi-
als were stored according to the manufacturer’s instruction.
For POC assays, quality control (QC) material provided by 
the manufacturers was measured before measurement of the first 
patient’s blood samples, and results were considered valid for 24 h. 
The imprecision profiles were generated by measuring patient’s blood 
samples five times, calculating mean concentrations, and CV%.
Statistical data analysis
Statistical analysis was performed using SPSS 23.0 (IBM, USA) and 
Analyse-it Method evaluation 4.65.3 (Microsoft, USA). The propor-
tional variance fit model was applied to calculate imprecision (CV%) 
Table 1: Characteristics of study population.
Study population (n = 90)
Age, mean ± SD, years 60 ± 17
Male sex 60 (67%)
Risk factors
 Hypertension 48 (53%)
 Diabetes mellitus 17 (19%)
 Current smoking 25 (28%)
 Hypercholesterolemia 31 (34%)
Medical history
 Coronary heart disease 28 (31%)
 Previous myocardial infarction 14 (16%)
 Previous revascularization or bypass surgery 11 (12%)
 Chronic kidney disease (eGFR < 60) 18 (20%)
Medication at the hospital admission
 Aspirin 31 (34%)
 β-Blocker 18 (20%)
 ACE inhibitor 14 (16%)
 ATII antagonists 22 (24%)
 Calcium antagonists 12 (13%)
 Diuretics 19 (21%)
 Nitrates 4 (4%)
 Statin 25 (28%)
 Anti-platelet agents 6 (7%)
ECG findings
 ACS specific 18 (20%)
 Other changes 30 (33%)
 Normal 42 (47%)
Chest pain onset
  > 3 h 79 (88%)
  > 6 h 63 (70%)
  > 24 h 34 (38%)
Final diagnosis
 STEMI 2 (2%)
 NSTEMI 15 (17%)
 Unstable angina pectoris 7 (8%)
 Other cardiac 12 (13%)
 Non-cardiac 54 (60%)
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at 99th percentiles reported by each manufacturer. The following 
number of samples was included in the model: 26, 31, 28, 41 and 30 
for cTn assay on Triage MeterPro, TnT AQT90 FLEX, TnI AQT90 FLEX, 
PATHFAST™ and Stratus CS 200, respectively. The receiver operat-
ing characteristic (ROC) curves were applied to measure diagnostic 
performance of cTn assays. To compare area under curves (AUCs), 
nonparametric z test was applied.
Evaluation of user-friendliness
Two independent users assessed the practical utility of the POC sys-
tems. The following aspects were assessed: (a) time factors: preana-
lytical and analytical time, and required training time; (b) stability 
and storage of QC material; (c) test stability; (d) operation facilities: 
sample preparation and volume, instrument design, hygiene, clean-
ing and maintenance.
Results
Study population
Ninety patients were enrolled in the study. Fifteen patients 
had NSTEMI, two STEMI and seven unstable angina pec-
toris. In 12 patients, chest pain had other cardiac causes, 
such as cardiac decompensation or pericarditis. In 54 
patients, chest pain was not related to any cardiac eti-
ology but caused by musculoskeletal and dyspeptic 
complaints or psychiatric problems in most cases. In 74 
patients (82%), at least one cardiovascular risk factor was 
present, and  28 patients (31%) had a history of coronary 
artery disease. The duration of chest pain at the hospital 
admission was longer than 6 h in 63 patients (70%).
The analytical quality of the POC assays
The imprecision and accuracy of the POC assays were 
assessed by single measurements of QC material provided 
by the respective manufacturer at two levels – except 
Triage MeterPro where only one level was provided (Table 3 
and Supplemental Figure 1). The imprecision of cTnT on 
AQT90 FLEX as well as cTnI on Triage MeterPro, Stratus CS 
200 and AQT90 FLEX level 2 corresponded to the manu-
facturer’s specifications. The imprecision of AQT90 FLEX 
cTnI on level 1 was slightly higher than the manufactur-
er’s quality specification. For PATHFAST™, the CV’s were 
twice as high as claimed by the manufacturer. Measured 
mean cTn concentrations differed significantly from target 
cTn concentrations provided by the manufacturers for the 
Triage MeterPro (34%), PATHFAST™ (11% for level 1 and 
−7.6% for level 2) and AQT90 FLEX cTnI level 1 (−15%).
The imprecision profiles with proportional variance 
fit model were used to assess both the imprecision (CV%) 
at the 99th percentile stated by the manufacturer and the 
functional assay sensitivity (FAS) defined as the lowest cTn 
concentration measured with an imprecision of 10% (Table 
4 and Figure 1). The manufacturer of the PATHFAST™ cTnI 
assay claims the imprecision of 5% at the 99th percentile 
Table 2: Characteristics of the cTn assays as defined by the manufacturer.
System   POC   Core-lab analyzer
Manufacturer   Alere   Radiometer   LSI Medience 
Corporation
  Siemens   Roche   Abbott
Name   Triage MeterPro 
mit next 
generation TnI
  AQT90 FLEX   PATHFAST™   Stratus CS 200   Elecsys 
Cobas 8000
  Architect 
i2000SR
Troponin   cTnI   cTnT   cTnI   cTnI   cTnI   hs-cTnT   hs-cTnI
Measuring  
range, ng/L
  10–10,000   10–25,000  10–50,000  1–50,000   30–50,000   3–10,000   10–50,000
99th  
percentile, ng/L
  20   17   23   20   70   14   26
CV (%) at 99th 
percentile
  <17   15   12   5.2   <10   <10   4
CV = 10% at 
concentration, ng/L
  37   26   27   3.1   60   13   4.7
Specimen   EDTA whole 
blood or 
plasma
  Heparin and EDTA whole 
blood or plasma
  Heparin and 
EDTA whole 
blood or plasma
  Heparin whole blood 
or plasma
  Serum, 
heparin and 
EDTA plasma
  Serum, 
heparin and 
EDTA plasma
Sample volume   250 μL   2 mL   100 μL   200 μL plasma or 
2–2.5 mL whole blood
  50 μL   210 μL
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that corresponds to 20 ng/L. However, we measured cTnI 
concentrations of 20 and 24 ng/L with imprecision of 
11.5% and 10%, respectively. Both the imprecision at the 
claimed 99th percentile and FAS of Stratus CS 200 cTnI 
corresponded well to the  manufacturer’s specifications 
(9.2% observed vs. <10% claimed and 64 ng/L observed 
vs. 60 ng/L claimed, respectively). For the TnI assay on 
AQT90 FLEX, both imprecision at the 99th percentile and 
FAS were even lower than the manufacturer’s specifica-
tion (7.4% observed vs. 12% claimed and 16 ng/L observed 
vs. 27 ng/L claimed, respectively). For the cTnT assay on 
AQT90 FLEX, the claimed and measured imprecision at 
the 99th percentile (17 ng/L) was practically identical 
(15% vs. 16%), whereas the FAS was higher than claimed 
(31 vs. 26 ng/L). The Triage MeterPro cTnI assay showed an 
extremely high imprecision at the 99th percentile (20 ng/L) 
of 40% (claimed <17%). The imprecision of 10% was only 
reached at cTnI concentrations as high as 840 ng/L.
Diagnostic performance of POC assays 
in the diagnosis of NSTEMI
ROC curve analyses were applied to estimate the diagnos-
tic performance of the cTn assays. For the calculations, 
patients with final diagnosis of NSTEMI were defined as 
cases, and patients with either other, non-cardiac chest 
pain or unstable angina pectoris were defined as con-
trols. Moreover, from these patients, blood samples had 
to be available at the hospital admission and 3 h later. The 
reference assays, Abbott hs-cTnI and Roche hs-cTnT had 
AUCs of 0.86 [95%  confidence interval (CI), 0.75–0.96] and 
0.88 (95% CI, 0.80–0.95), respectively, at hospital admis-
sion, and of 0.96 (95% CI, 0.92–1.00) and 0.94 (95% CI, 
0.88–0.99), respectively, 3 h later. At hospital admission, 
cTnT assay on AQT90 FLEX reached AUC of 0.74 (95% CI, 
0.59–0.89), and cTnI assays on AQT90 FLEX, PATHFAST™ 
and Stratus CS 200 reached AUCs of 0.84 (95% CI, 0.71–
0.96), 0.90 (95% CI, 0.82–0.97) and 0.76 (95% CI, 0.62–
0.90), respectively, which were not significantly different 
from that of the Abbott hs-cTnI assay. By contrast, Triage 
MetePro cTnI assay with AUCs of 0.71 (95% CI, 0.53–0.89) 
performed significantly worse than the hs-cTnI assay. The 
performances of cTnI assays on Triage Meter Pro, AQT90 
FLEX and PATHFAST™ were statistically comparable, 
whereas Stratus CS 200 cTnI and AQT90 FLEX TnT assays 
were worse than Roche hs-cTnT assay at the time point 
of the hospital admission (Table 5, Figure 2 and Supple-
mental Table 1). Significant increases in AUC for meas-
urements of samples obtained 3  h postadmission were 
Table 4: Imprecision and functional assay sensitivity of the cTn POC assays derived from measurement of patients’ whole blood samples.
PATHFAST™ Stratus CS 200 AQT90 FLEX cTnI AQT90 FLEX cTnT Triage MeterPro
Claimed Measured Claimed Measured Claimed Measured Claimed Measured Claimed Measured
99th percentile, ng/La 20 – 70 – 23 – 17 20 –
CV (%) at 99th 
percentile
5 11.5 <10 9.2 12 7.4 15 16 <17 40
Functional assay 
sensitivity (FAS)b, ng/L
3 24 60 64 27 16 26 31 37 840
Classification Guideline 
acceptable
Clinically 
usable
Guideline 
acceptable
Guideline 
acceptable
Clinically 
usable
Guideline 
acceptable
– Clinically 
usable
Clinically 
usable
Not 
acceptable
aDefined by the manufacturer. bDefined as the concentration which was measured with CV of 10%.
Table 3: Analytical quality of the cTn POC assays using QC material provided by manufacturers.
POC System   Control material   Target cTn 
concentration, ng/L
  Measured mean cTn 
concentration, ng/L
  Bias, %  CV%
PATHFAST™   QC level 1   73  81  11  7.7
  QC level 2   1370  1266  −7.6  8.0
Stratus CS 200   QC level 2   942  944  0.2  2.9
  QC level 3   3890  3977  2.2  4.5
AQT90 FLEX cTnI   MC1   36  31  −15  11
  MC2   1120  1127  0.6  3.7
AQT90 FLEX cTnT   TnT1   56  56  0.8  5.1
  TnT2   853  884  3.6  2.8
Triage MeterPro   Triage total level 1  40  54  34  13
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observed for both hs-cTn and AQT90 FLEX cTnT assays. In 
turn, statistical significance for the increase in AUC was 
marginally missed for cTnI assays on Triage MeterPro and 
PATHFAST™ (Table 5, Figure 2 and Supplemental Table 2). 
There were no statistical differences in AUC between cTnI 
assays on Stratus CS 200 and AQT90 FLEX. Furthermore, 
3  h postadmission, all POC assays performed equally as 
the hs-cTn assays (Supplemental Table 1).
At the time point of the hospital admission, the 
PATHFAST™ cTnI assay showed a similar performance 
as the AQT90 FLEX cTnI assay but was superior to the 
cTnI assays Triage MeterPro and Stratus CS 200 as well 
as to the AQT90 FLEX cTnT assay. Three-hour postadmis-
sion, there was no statistical difference between PATH-
FAST™ cTnI assay and other POC assays ( Supplemental 
Table 3).
At the 99th percentile cutoff concentration claimed 
by the manufacturers and at the time point of a patient’s 
admission to the emergency department, the referent 
Abbott hs-cTnI and Roche hs-cTnT assays had sensitivi-
ties of 62% (95% CI, 35–82%) and 92% (95% CI, 67–99%), 
respectively, and negative predictive values (NPVs) of 92% 
Figure 1: Imprecision profiles of POC assays.
Blue dotted line – limit of detection; black dashed line – 99th percentile of the healthy population; green line – imprecision of 10% (guide-
line acceptable); red line – imprecision of 20% (clinically usable).
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(95% CI, 86–96%) and 98% (95% CI, 88–100%), respec-
tively. At this time point, PATHFAST™ cTnI assay had the 
highest sensitivity of 67% (95% CI, 39–86%) and NPV of 
93% (95% CI, 86–97%) of all POC assays. In general, sen-
sitivities of POC were statistically equal to the sensitivity 
of Abbott hs-cTnI assay and with the exception for PATH-
FAST™ cTnI assay inferior to the sensitivity of Roche 
hs-cTnT assay (data not shown). At the time point of the 
second cTn measurement 3 h postadmission, the referent 
Abbott hs-cTnI and Roche hs-cTnT assays had sensitivities 
of 77% (95% CI, 50–92%) and 100% (95% CI, 77–100%), 
respectively, and NPVs of 95% (95% CI, 88–98%) and 
100%, respectively. Stratus CS 200 cTnI assay had the same 
 sensitivity and NPV of 77% (95% CI, 50–92%) and 95% (95% 
CI, 88–98%), respectively, as the Abbott hs-cTnI assay. The 
other POC assays had lower sensitivities ranging from 62% 
(95% CI, 36–82%) for the AQT90 FLEX cTnT assay to 75% 
(95% CI, 47–91%) for the PATHFAST™ cTnI assay. Three-
hour postadmission, NPVs of the POC cTn assays ranged 
between 92% and 95% and, hence, were within the range 
of the Abbott hs-cTnI assay (Table 5).
Practicability
Detailed information on user friendliness is provided in 
Supplemental Table 4. The main advantage of the Triage 
MeterPro is its very small, portable size. The QC material 
is provided in the practical single-use ampules that can be 
thawed directly before use. PATHFAST™ allows simula-
tions measurements of up to six samples (patient’s blood 
and QC). Both Triage MeterPro and PATHFAST™ require 
pipetting of the blood sample into the test cartridge, 
risking measurement errors by non-proper mixing of 
blood samples before pipetting. This sample handling also 
exposes users to accidental contact with blood. Because 
blood collection tubes can be placed directly into the 
device, AQT90 FLEX does not require any blood sample 
preparation. Although 2 mL of blood is needed in the col-
lection tube, actually only 15–20 μL is used for the analy-
sis. The AQT90 FLEX test cartridges containing 16 tests 
that can be stored on board for up to 2 weeks; therefore, it 
allows immediate sample measurement. Moreover, AQT90 
FLEX is the only tested device, which does not impose any 
contact with blood, reagents or waste and thereby reduces 
the exposure to biohazards to the minimum. By analyz-
ing plasma instead of full blood, Stratus CS 200 offers 
two measurement options: either directly from the blood 
collection tube, requiring 2.5  mL of whole blood, with 
on board centrifugation, thereby minimizing exposure 
to biohazards, or precentrifuged plasma in the test cup. Ta
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Moreover, Stratus CS 200 was the largest from the tested 
POC devices and requires daily system check.
Discussion
The hs-cTn assays performed in central laborato-
ries display high clinical sensitivity and specificity as 
requested by guidelines for the rule-out and rule-in, 
respectively, of NSTEMI in patients presenting with chest 
pain at the emergency department. However, due to blood 
sample transport and processing, the turnaround time of 
these hs-cTn assays amounts to 1 h or more [5]. POC assays 
shorten turnaround times by avoiding the transport of 
samples to the central laboratory and facilitated sample 
handling and preparation. Thereby, POC cTn assays have 
the potential to reduce the length of stay of NSTE-ACS 
patients in the emergency department and to lower hospi-
tal costs [6–8]. In the same time, a randomized controlled 
trial of POC cTn assays in the emergency department 
does not find any clinical benefit of cTn testing by POC as 
compared to the cTn testing in the central laboratory [9]. 
Nonetheless, potential advantage of POC testing in reduc-
ing length of stay of patients with suspected NSTE-ACS in 
the emergency department can only take place if the POC 
cTn assays are as sensitive as the hs-cTn assays used in the 
central laboratories.
For the fast and reliable rule-out, cTn assay must be 
very precise with an imprecision of <10% CV at the 99th 
percentile encountered among healthy individuals [10]. 
In our study 99th percentile cutoffs were provided by the 
manufacturers of the assays. With this limitation, score-
card requirement for guideline-acceptable hs-cTn assays 
[4] was achieved by the cTnI assays run either on Stratus 
CS200 or on AQT90 FLEX. A CV of less than 20% at the 
99th percentile is still considered clinically acceptable, 
as it does not significantly increase the false-positive 
diagnoses of myocardial infarction [4, 10]. This condition 
was fulfilled by the PATHFAST™ cTnI assay, which was 
previously claimed to be guideline acceptable, as well as 
by the AQT90 FLEX cTnT assay. According to the scorecard 
criteria [4], the CV of 40% at the clinical decision cutoff 
classifies the Triage MeterPro cTnT assay as too imprecise 
for clinical utility. However, this very high imprecision 
can be partially explained by the device’s reporting con-
centrations only roughly discriminated by 10 ng/L steps. 
Our finding of higher imprecision of most POC assays and 
hence lower scorecard classification than claimed by the 
manufactures has two potential explanations. First, we 
analyzed whole blood samples rather than accustomed 
plasma samples. Second, the number of samples might 
not be sufficient to construct reliable imprecision curves.
A more direct measure of clinical utility of cTn assay 
is its diagnostic performance. In our study, NSTEMI was 
ruled out by the finding of two negative test results (0 h, 
3 h) of Roche hs-cTnT measurements in the central labo-
ratory. By this study design, the Roche hs-TnT assay was 
defined as the gold standard, which cannot be surpassed 
by any other assay. To avoid this bias, we included the 
Abbott hs-TnI assay, which in several large studies showed 
the same diagnostic performance as the Roche hs-TnT 
assay [11, 12]. In our hands, Abbott hs-TnI was consider-
ably less sensitive than Roche hs-TnT both at admission 
(62% vs. 92%) and 3  h later (77% vs. 100%). Thus, it is 
more appropriate to compare the data on the diagnos-
tic performance of the POC cTn assays with those of the 
Abbott hs-cTnI assay rather than with those of the Roche 
hs-TnT assay.
In our hands, the PATHFAST™ cTnI assay showed the 
best diagnostic performance of all POC cTn assays, which 
is in line with the excellent FAS claimed by the manufac-
turer rather than with the intermediate FAS found by us. 
The PATHFAST™ cTnI assay performed similarly to the 
referent Abbott hs-cTnI assay. Therefore, it qualifies as a 
Figure 2: ROC curves of cTn assays at the hospital admission (0 h) and 3 h later.
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candidate for the application of the 0/1 h algorithm pro-
posed by ESC [2]. Conversely, despite their excellent FAS 
qualifying them as guideline acceptable assays, the cTnI 
assays run on Stratus CS 200 and AQT90 FLEX showed 
very low diagnostic sensitivity at the time point of hospital 
admission, which however improved markedly, especially 
for the Stratus CS 200 cTnI assay, when cTnI measurement 
was repeated 3 h postadmission. One possible reason for 
the discrepancy between analytical and diagnostic perfor-
mance of the cTnI assays run on PATHFAST™, Stratus CS 
200 and AQT90 FLEX may be caused by the definition of 
the 99th percentile, which is not standardized and thus 
can vary due to the demographics and screening methods 
used to exclude cardiac disease [13]. Therefore, the 99th 
percentile may be higher than reported for PATHFAST™ 
but lower than reported for Stratus CS 200 and AQT90 
FLEX. The Triage MeterPro cTnI and AQT90 FLEX cTnT 
assays showed the weakest diagnostic performance at 
time point of hospital admission.
To our knowledge, our study for the first time had sys-
tematically compared the diagnostic performance of five 
POC cTn assays and two core-lab hs-cTn assays according 
to the 0/3  h algorithm recommended by ESC guidelines 
for the management of NSTE-ACS patients [2]. By includ-
ing the Abbott hsTnI test as a second reference assay, we 
reduced the bias of the Roche hs-cTnT assay, which was 
used as the criterion for the rule-out of NSTEMI, and 
therefore by definition reached 100% sensitivity and 
NPV in samples obtained 3 h after admission to the hos-
pital. The most substantial weakness of our study is the 
limited sample size. However, the setting of our study that 
requires immediate measurement of fresh blood samples 
using five different assays only allowed to investigate 
patients hospitalized during regular working days and 
hours and prevented the large numbers of previous mul-
ticentre studies, where plasma samples from bioreposi-
tories were analyzed by core-labs [14]. To ensure that our 
study still provides substantial information on differences 
in the analytical and clinical performance of the evaluated 
POC cTn assays, we performed ROC power analysis. For 
the average number of NSTEMI patients and controls of 
12 and 65, respectively, the a priori power was 94%, which 
is considered as high value of experimental replicability, 
and therefore our sample size is sufficient to provide reli-
able results (data not shown). A protocol and study like 
ours can help to select POC cTn assays, which are likely to 
reach the analytical and diagnostic performance needed 
for the management of the NSTE-ACS patients according 
to ESC guidelines. A top candidate like the PATHFAST™ 
cTnI should then be tested in larger and multicentric 
studies [15].
In conclusion, our strictly controlled study identi-
fied the PATHFAST™ cTnI assay as the only one, whose 
diagnostic performance is comparable to that one of the 
Abbott hs-cTnI assay used in the central laboratory. Thus, 
it has the best chance to allow the clinical management 
of NSTE-ACS patients as safely as fully automated hs-cTn 
assays at the benefit of shortened turn-around time.
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